Get the Stockscreener App
15.19
1.68%
-0.26
Contineum Therapeutics Inc stock is traded at $15.19, with a volume of 279.31K.
It is down -1.68% in the last 24 hours and up +34.42% over the past month.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
See More
Previous Close:
$15.45
Open:
$15.4
24h Volume:
279.31K
Relative Volume:
0.88
Market Cap:
$567.90M
Revenue:
$50.00M
Net Income/Loss:
$-58.44M
P/E Ratio:
-7.779
EPS:
-1.9527
Net Cash Flow:
$-57.73M
1W Performance:
+0.60%
1M Performance:
+34.42%
6M Performance:
+63.16%
1Y Performance:
+276.92%
1-Day Range:
$14.84
$15.53
1-Week Range:
$14.43
$16.00
52-Week Range:
$3.72
$16.91
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
15.19 | 567.90M | 50.00M | -58.44M | -57.73M | -1.9527 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Sep-25-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | William Blair | Outperform |
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
View All
Contineum Therapeutics Inc Stock (CTNM) Latest News
Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock - Investing.com UK
Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock By Investing.com - Investing.com Nigeria
Form 4 Contineum Therapeutics Inc For: 10 July By Investing.com - Investing.com Nigeria
Contineum Therapeutics (NASDAQ: CTNM) CSO sells 1,040 shares, exercises options - Stock Titan
Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice - MSN
Form 4 Contineum Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
Contineum Therapeutics CEO Stengone sells $40,000 in shares By Investing.com - Investing.com South Africa
Price to sales forward of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView
Contineum Therapeutics CEO Stengone sells $40,000 in shares - Investing.com
Contineum (CTNM) CEO sells 2,500 shares under Rule 10b5-1 plan - Stock Titan
Form 144 Contineum Therapeutics For: 8 July By Investing.com - Investing.com South Africa
CTNM insider selling 2,500 shares via option exercise; prior 10,000-share 10b5-1 sale - Stock Titan
Price to earnings forward of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference - AOL.com
Enterprise value to revenue forward of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView
Price to book forward of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView
Enterprise value to EBIT forward of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView
CTNM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Continued Clinical ProgressEstimate Uncertainty - dars.gov.et
Contineum Therapeutics CSO Daniel Lorrain sells $594,578 in stock By Investing.com - Investing.com South Africa
Contineum Therapeutics CSO Daniel Lorrain sells $594,578 in stock - Investing.com
Contineum (NASDAQ: CTNM) CSO sells 37,179 shares and exercises 33,009 options - Stock Titan
Contineum Therapeutics CEO Stengone sells $160,080 in stock By Investing.com - Investing.com Australia
Contineum Therapeutics CMO Tim Watkins sells $173,590 in company stock - Investing.com UK
Contineum Therapeutics CMO Tim Watkins sells $173,590 in company stock By Investing.com - Investing.com Nigeria
Form 4 Contineum Therapeutics Inc For: 1 July By Investing.com - Investing.com Nigeria
Contineum Therapeutics (CTNM) Sees 9.2% Pre-Market Surge - GuruFocus
Contineum (NASDAQ: CTNM) CMO sells 10,833 shares after option exercise - Stock Titan
Contineum Therapeutics CEO Stengone sells $160,080 in stock - Investing.com
[Form 4] Contineum Therapeutics, Inc. Insider Trading Activity - Stock Titan
Form 144 Contineum Therapeutics For: 1 July By Investing.com - Investing.com India
Insider sales and option exercise at CTNM (NASDAQ: CTNM) - Stock Titan
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry - BioSpace
Form 144 Contineum Therapeutics For: 30 June By Investing.com - Investing.com Nigeria
Contineum publishes discovery data on LPAR1 antagonist PIPE-791 - Investing.com
CTNM (NASDAQ) notice to sell 28,826 shares; broker Morgan Stanley named - Stock Titan
[144] Contineum Therapeutics, Inc. SEC Filing - Stock Titan
Contineum publishes discovery data on LPAR1 antagonist PIPE-791 By Investing.com - Investing.com India
Contineum Therapeutics, Inc.(NasdaqGS: CTNM) added to Russell 2000 Index - marketscreener.com
Contineum Therapeutics, Inc.(NasdaqGS: CTNM) added to Russell 2000 Value Benchmark - marketscreener.com
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):